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Abstract
Background:  Sex hormones have a pronounced effect on arginine vasopressin (AVP), and
therefore on the diurnal water homeostasis. Low and high levels of plasma-estradiol as seen in the
follicular phase of the menstrual cycle may therefore alter the diurnal regulation of urine
production. Furthermore the structural resemblance of oxytocin to vasopressin has led to
speculations about the possible antidiuretic properties of oxytocin under normal physiological
conditions. To elucidate the influence of high and low p-estradiol on the regulation of the diurnal
urine production, 15 normal menstruating women (21–33 y) underwent two circadian in-patient
investigations, both situated in follicular phase.
Methods: Admitting the participants solely in the follicular phase resulted in high and low plasma-
estradiol whereas plasma-progesterone was similar. Urine and blood samples were taken at
predetermined time points to determine plasma AVP, plasma oxytocin, plasma aldosterone, plasma
natriuretic peptide (ANP), urinary solute excretions, and urinary excretions of prostaglandin E2
(PGE-2) and aquaporin-2 (AQP-2). Blood pressure was measured every hour.
Results: Plasma AVP, plasma aldosterone and plasma ANP were unaffected by the different levels
of estradiol. All had marked circadian variations whereas oxytocin did not display any circadian
rhythm. High estradiol resulted in lower p-osmolality and p-sodium reflecting the downward
resetting of the osmoreceptors. Oxytocin did not correlate with either diuresis or urine
osmolality. The diurnal urine production was similar in the two groups as were urine osmolality,
excretion of PGE-2 and AQP-2. AQP-2 does not have a circadian rhythm and is not significantly
correlated to either AVP or oxytocin under normal physiological conditions.
Conclusion: High and low level of estradiol has no influence on the circadian rhythm of AVP or
the subsequent urine production. High p-estradiol resets the osmoreceptors for AVP release.
Furthermore it appears that oxytocin under normal physiological conditions do not contribute to
the overall antidiuretic effect.
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Background
The transition from day to night lead to a pronounced
decrease in diuresis and a reduction in excretion of elec-
trolytes in both sexes. The secretion of AVP, one of the
most important hormones in the human water homeosta-
sis increases at night. The diurnal rhythm of AVP is most
pronounced in tween-agers [1], whereas the rhythm in
adolescents is attenuated [2]. A diurnal rhythm all though
less marked exist in adult males as well [3-6]. Circulating
AVP is influenced by ovarian steroid blood levels and var-
ious studies have shown changing AVP concentration dur-
ing the normal menstrual cycle in women [7,8]. Other
studies have failed to confirm any variation [9-12]. Estro-
gen unopposed to progesterone given to postmenopausal
women will increase AVP, whereas the combination of
estrogen and progesterone will decrease AVP [13-16].
Only a few circadian studies of AVP have been conducted
in females [8,17,18]. One study in premenopausal
women has demonstrated both increased basal and noc-
turnal concentration of AVP in midfollicular phase of the
menstrual cycle [8]. Another study has shown decreased
circadian rhythm in young women compared to young
age-matched men, but are without control for menstrual
status in the young women [18]. Stimulated release of
vasopressin is influenced by sex hormones as well. Base-
line plasma-osmolality and sodium are decreased in high
estrogen states due to a resetting of the osmoreceptors for
thirst and AVP release [9,10,12,19-21]. In spite of the
lower plasma osmolality, AVP secretion persists, reducing
clearance of free water and maintaining slightly hypotonic
plasma.
The structural resemblance of oxytocin to AVP has led to
speculations of a possible additive antidiuretic effect of
oxytocin. Exogenous oxytocin in doses above the normal
range is clearly antidiuretic [22,23], and since estrogen
increases the concentration of oxytocin [8,24,25], it is
obvious to compare the antidiuretic effect of oxytocin in
different estrogen states. Observations concerning the
diurnal rhythm of oxytocin over the course of a normal
menstrual cycle are however sparse [8] and the role of oxy-
tocin as an antidiuretic hormone under normal physio-
logic conditions remains to be clarified. Since the
hormones involved in the diurnal urine regulation one
way or another all are influenced by the female sex-hor-
mones, it seems reasonable to test the hypothesis that dif-
ferent levels of estrogen alters the diurnal regulation of
urine production. To identify the effect of different con-
centrations of estrogen on the diurnal urine regulation,
the volunteers were admitted twice and solely in the fol-
licular phase, in which progesterone is low. We hypothe-
sized that: 1) AVP and the nocturnal peak are augmented
in women with high endogenous estrogen compared to
women with low endogenous estrogen. The urine produc-
tion will subsequently be decreased and urine osmolality
increased in the high estrogen-state. 2) Oxytocin would be
enhanced when endogenous estrogen rises preovulatory
and may subsequently affect the diurnal urine regulation.
Methods
Fifteen healthy non-smoking women were recruited by
advertisement at the University of Aarhus. The partici-
pants should have a normal reproductive history and the
natural cycling women should have regular menstrual
cycles (26–33 days). They should not have nocturia or any
other urological complaints, no previous surgery, no his-
tory of renal, cardiac or hepatic disease and a normal
physical examination (gynecologic examination
included), normal office blood pressure, normal blood
chemistry, normal urine-analysis (no bacteuria, proteinu-
ria or glucosuria), normal uroflowmetry and no post void
residual volume assessed by ultrasound estimation.
No medication should be taken for at least 1 month
before and during the investigation. All participants vol-
unteered to the study after information of its nature and
purpose, which conformed to the guidelines, contained in
the Declaration of Helsinki, with a prior approval by the
Local Ethics Committee in Aarhus County and the Danish
Data Protection Agency.
In the preceding cycle the participants twice completed a
3-day frequency/volume chart (FVC). Time and volume
(ml) of each micturition and of each fluid intake were
noted. Intake of fluid and food was ad libitum and the sub-
jects were allowed to ambulate at will. No restrictions
were instigated regarding type of foods or fluids. The par-
ticipants were asked not to alter their habits during the
measuring period. The time of rising and the bedtime was
noted.
The participants were admitted twice. To plan the dates for
the two admissions, data from the three latest cycles in
each participant were used. Admissions took place in the
follicular phase in which progesterone remains low. The
first admission being in the middle of the follicular phase
representing a low estrogen phase and the second 5 days
later just before estimated time of ovulation representing
a high estrogen phase. Two days prior to the admissions,
the participants were fluid preconditioned to 30 ml/kg
body weight/24 h. The participants were told to refrain
from alcohol and caffeinated beverages and heavy physi-
cal activities 24 h before the admission. The participants
were then admitted to the hospital for 25 hours.
Upon arrival an intravenous catheter was inserted in the
antecubital vein in the non-dominant arm. Blood-sam-
ples were obtained at 8, 14, 20, 23, 2, 5, and 8 hours. A
total amount of 210 ml blood was drawn. The blood sam-
ples were replaced by isotonic saline.BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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Participants were seated in a chair 30 min before blood
sampling during the day (0800 to 2300 h). During the
night (2300 to 0800 h) samples were taken in the supine
position. Blood samples were centrifuged at +4°C and
plasma samples were stored at -80°C unless immediately
analyzed. Parameters analyzed were atrial natriuretic pep-
tide (ANP), AVP, estradiol, oxytocin, and prolactin, pro-
gesterone, testosterone, FSH and LH. Creatinine (Pcr),
packed cell volume (PCV), potassium (PK), osmolality
(Posm), and sodium (PNa) were analyzed as well.
Blood pressures were monitored by cuff every hour with
an automatic ambulatory blood pressure monitor (ABP
Monitor 90207 ™ SpaceLabs Medical, Inc, Redmond, WA,
USA).
Urine was collected every three hours from 0800 to 2300
hours. Night-time urine production was represented by
one sample (2300-0800 h). Urine volume (Uvol) and the
concentration of creatinine (Ucr), osmolality (Uosm),
potassium (UK), and sodium (UNa) as well as prostaglan-
din E2 (PGE-2) and aquaporin-2 (AQP-2) were measured.
During admission a total fluid intake of 30 ml/kg body
weight/24 h of tap water, distributed equally during the
day was allowed. Meals with known contents of sodium
(3 mmol/kg/day), potassium, calcium, and calories were
served at 0800, 1200, and 1800 hours.
Blood and urine analyses
Plasma and urine concentration of sodium, potassium
and creatinine, PCV, plasma concentration of estradiol,
progesterone, prolactin, testosterone, FSH, and LH were
measured using routine procedures. Plasma and urine
osmolality were measured using the freezing point
depression method (Advanced™ Osmometer model 3900,
Advanced Instruments, Norwood, MA, USA).
Analyses of hormones
AVP was determined in plasma by radioimmunoassay
(RIA)[26], using a highly specific AVP antibody (AB3096)
as previously described by [27]. AVP was extracted from
plasma using Sep-Pak®  Plus C18 extraction cartridge
(Waters Corporation, Milford, MA, USA). The detection
limit was 0.10 pg/ml plasma and the intra- and inter-assay
coefficients of variation were 7.7% and 10.6%, respec-
tively.
ANP was measured in plasma following extraction on
Sep-Pak® Plus C18 extraction cartridge (Waters Corpora-
tion, Milford, MA, USA) by means of a RIA using a sheep
ANP specific antibody (1023BANI1, Euro-diagnostica,
Arnhem, The Netherlands). The detection level was 3.5
pg/ml, whereas inter- and intra-assay coefficients of varia-
tion were 11.6% and 8.6% respectively.
Aldosterone was measured without extraction by means
of a RIA using a rabbit antibody (DSL-8600, Diagnostic
Systems Laboratories, Inc., Webster, Texas, USA). Detec-
tion level 7.64 pg/ml. Inter- and intra-assay was 8.2% and
3.9% respectively.
Oxytocin was measured in plasma following extraction on
Sep-Pak® Plus C18 extraction cartridge (Waters Corpora-
tion, Milford, MA, USA) by RIA using an oxytocin-specific
rabbit-antibody kindly provided by Dr. M. Morris, Day-
ton, OH, USA. The detection level was 0.9 pg/ml, whereas
inter- and intra-assay coefficients of variation were 11.0%
and 7.5% respectively.
Urine analyses
A commercial enzyme immunoassay kit (Amersham
Pharmacia Biotech, Little Chalfont, UK) was used to deter-
mine the PGE2 excretion in the urine. The analysis was
performed without prior extraction. Inter-assay and intra-
assay were approximately 13% and 9%. The detection
limit was 40 pg/ml urine.
Urinary AQP2 was measured by radioimmunoassay using
a modification of previous established methods [28-30].
Detection limit was 16 pg/ml urine.
Calculations
Based on the measurements, excretion rates (E) and clear-
ances (C) were calculated for electrolytes, creatinine and
osmoles (osm) using standard formulas. Glomerular fil-
tration rate (GFR) was estimated from creatinine clearance
(Ccr). Fractional excretions (FEx) was calculated as Cx/
GFR*100. Solute free water reabsorption (TC H2O) is Cos-
mol-Uvol.
Statistical analyses
To compensate for the variability of body weight in the
study population urinary excretion rates are expressed per
kg body weight. Participants who had a mean p-estradiol
below 0.5 nmol/l in the first admission and at least a 75%
increase in p-estradiol to the second admission were
included in the statistical analysis. To detect effects in p-
AVP of approximately 0.20 or greater, the sample size was
estimated to 7 using pair wise comparisons. A = 0.05 and
β = 0.2.
To compare the evolution over time for the two groups,
we used a mixed effect ANOVA with a subject specific ran-
dom effect and using time and group as fixed effects, as
well as their interaction if this was statistically significant
(Wald's test). When quantifying the day-night differences
we created an indicator variable (day at time points 0800,
1400, 2000, and 2300 and night at time points 0200,
0500, and 0800) and used this variable in place of time in
the mixed effect model. When appropriate the data wereBMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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log-transformed to fit the statistical model. These data are
presented as geometric mean with normal 95% confi-
dence intervals. Regarding the home recordings, 24 h, day
and night time parameters were calculated and differences
between day and night were compared with Student's t
tests. Correlations were calculated using Pearson's correla-
tion. When correlating parameters obtained from both
blood and urine, only simultaneously taken blood sam-
ples and urine samples were correlated.
The results are presented as mean ± SD. Non-detectable
values were set to equal half the detection level. One of the
participants is excluded from the analysis of PGE-2,
because she had three extreme outliers of unknown origin
in her second admission. Results were considered signifi-
cant at p < 0.05.
Results
Seven of the admitted women were excluded prior to the
statistical handling due to either low or medium estrogen-
levels in both admissions; this assumed to be due to irreg-
ularity in the menstrual cycle at the time of investigation.
The analysis thus includes 8 women (mean age 25.0 years,
range 23–26 years; bodyweight 64.6 kg, range 56–78 kg)
who fulfilled the criteria of a mean p-estradiol below 0.5
nmol/l in the first admission and at least a 75% increase
in p-estradiol to the second admission.
Home-recordings
During the home-recording period, all of the 8 included
participants completed the FVC for 2 times 3 days and
nights. There was no difference in any of the measured
parameters between the two 3-day periods. In total 2 noc-
turia nights and 46 no-nocturia nights were recorded. The
24 h fluid-intakes at home were 30.3 ± 6.2 ml/kg. The
fluid intake at home did not differ from the fluid intake in
the inpatient studies. Both 24 h urine volume and day-
time urine volume during admissions 1 and 2 were signif-
icantly higher than in the home-recordings. Day/night
ratio was similar in both admissions and in the home-
recordings (Table 1).
Urine excretions
24-hour and night time urine volume were similar in the
two admissions (Table 2) and a statistically significant
decrease in urine output from day to night was registered.
Two participants experienced nocturia in one of their
admissions (at 0500 h and midnight, respectively) accom-
panied by a decreased day/night ratio.
Urine-production peaked between 2000 and 2300 hours
and the lowest diuresis was seen at night (p < 0.001) (Fig.
1).
In both admissions a night time increase in urine osmola-
lity was seen (p < 0.01). No difference was found between
the two admissions for the overall 24 h excretion of
sodium, potassium, osmoles, AQP-2 or PGE2 (Table 2).
Except for AQP-2, there was a marked decrease in excre-
tion during night time in both admissions. Similar results
were obtained for CNa, CK, and Cosm. There was, however
a tendency towards decreased clearance of sodium, excre-
tion of sodium and fractional excretion of sodium in
women with high estrogen, but it did not quite reach sta-
tistical significance (p = 0.080, p = 0.063 and p = 0.074,
Fig. 1+2).
We found no diurnal variation in glomerular filtration
rate estimated by creatinine clearance (CCr) or in solute
free water reabsorption (TC). There was no change in GFR
or solute free water reabsorption between the two admis-
sions (p = 0.52 and p = 0.16, respectively, Fig. 2).
Measurements of plasma variables
Plasma osmolality had no diurnal variation, but was
lower in the second admission (high estrogen). The differ-
ence between p-osmolality in the two admissions: 2.46 ±
0.62 mosm/kg, (95%: 1.23–3.70, p < 0.001). Plasma
sodium concentration showed significant diurnal varia-
Table 1: Fluid intake and urine production at home assessed from a frequency volume chart (FVC) and during the in-patient studies (1. 
and 2. admission)
Mean ± SD
Registered days 
and nights
Nocturia nights Fluid intake 
(ml/kg)
24 h urine 
production 
(ml/kg)
Day time urine 
production 
(ml/kg)
Night time urine 
production 
(ml/kg)
Day/night ratio
Home 48 2 30.27 ± 6.19 26.93 ± 6.00 22.08 ± 7.74 5.98 ± 1.00** 3.98 ± 2.04
1. admission 8 1 30 38.42 ± 8.80¶ 31.28 ± 9.14¶ 7.14 ± 2.43*** 4.86 ± 2.43
2. admission 8 1 30 40.88 ± 6.09¶¶ 33.12 ± 8.83¶¶ 7.76 ± 5.42** 5.92 ± 3.81
Values are mean ± SD. ** day/night p < 0.01, *** day/night p < 0.001, ¶ Home/in-patient p > 0.05, ¶¶ Home/in-patient p > 0.01BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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tion with a reduction in concentration at night (p <
0.001). Women with high estrogen (2. admission) had
significantly lower plasma sodium, the difference
between p-sodium in the two admissions: 0.51 ± 0.18
mmol/l (95%: 0.15–0.87, p = 0.005), figure 3. Plasma cre-
atinine had in both admissions a diurnal variation with
an increase of 7.06 ± 2.31 μmol/l, (95%: 2.53–11.59, p =
0.002) at 2000 hours.
There was a small, but consistent reduction in packed cell
volume between the two admissions: 1.03 ± 0.28%,
(95%: 0.48–1.58, p < 0.001). Furthermore, we observed a
minimal night time decrease (1.34 ± 0.41%, (95% CI:
0.53–2.14, p < 0.001) compared to mean daytime values.
Hormones
Mean p-estradiol-concentrations during the two admis-
sions are presented in table 3. P-AVP and p-ANP were
unaffected by phase of menstrual cycle. For both hor-
mones we found a significant circadian rhythm (Fig. 4).
AVP increased at night. The ratio between geometric mean
day time and mean night time was 1.46 ± 0.15 pg/ml, p <
0.001, whereas ANP did not have a nocturnal increase (p
= 0.52). For prolactin we found a marked circadian varia-
tion with a consistent peak at 0200 hours (p < 0.001). A
significant difference was found between the groups as
well; as prolactin levels were higher in women with high
estrogen (p = 0.006). Plasma oxytocin was increased
along with estradiol but showed no circadian rhythm (p =
0.58). A clear diurnal variation was also evident for p-
aldosterone levels. The plasma levels of the hormone
markedly declined towards the evening and the first hours
of the night to continuously rise hereafter until the early
morning. There were no differences in the concentration
of progesterone; 3.44 ± 2.22 vs. 3.45 ± 1.01 nmol/l (p =
Table 2: Renal clearances and urinary excretions during the two admissions (1 and 2)
Mean ± SD
1. admisission 2. admission
Day Night 24 h Day Night 24 h
Uflow(ml/kg/h) 2.13 ± 0.58 0.76 ± 0.27*** 1.62 ± 0.34 2.22 ± 0.55 0.83 ± 0.56*** 1.70 ± 0.23
Uosm (mosm/kg) 431 ± 112 550 ± 126** 476 ± 90 382 ± 111 549 ± 181** 445 ± 80
ENa (mmol/kg/h) 0.16 ± 0.05 0.07 ± 0.02*** 0.13 ± 0.03 0.14 ± 0.04 0.07 ± 0.05*** 0.12 ± 0.03
CNa (ml/kg/h) 1.19 ± 0.35 0.45 ± 0.14*** 0.91 ± 0.20 1.04 ± 0.27 0.46 ± 0.33*** 0.83 ± 0.23
FENa (%) 0.92 ± 0.33 0.36 ± 0.11*** 0.71 ± 0.20 0.80 ± 0.23 0.37 ± 0.32*** 0.64 ± 0.21
EK (mmol/kg/h) 0.06 ± 0.02 0.02 ± 0.01*** 0.04 ± 0.01 0.06 ± 0.02 0.02 ± 0.01*** 0.04 ± 0.01
CK (ml/kg/h) 13.92 ± 3.36 4.86 ± 1.84*** 10.52 ± 2.35 14.72 ± 5.34 4.66 ± 2.46*** 10.95 ± 3.04
FEK (%) 11.51 ± 3.44 3.83 ± 1.36*** 8.63 ± 2.31 11.51 ± 4.05 4.16 ± 1.71*** 8.75 ± 2.48
Eosm (mmol/kg/h) 0.76 ± 0.11 0.45 ± 0.10*** 0.64 ± 0.08 0.72 ± 0.10 0.45 ± 0.16*** 0.62 ± 0.10
Cosm (mosm/kg/h) 2.68 ± 0.37 1.40 ± 0.31*** 2.20 ± 0.25 2.54 ± 0.38 1.43 ± 0.53*** 2.12 ± 0.36
CCr (ml/kg/h) 132.45 ± 16.29 126.99 ± 17.87 130.30 ± 19.72 134.43 ± 18.35 133.20 ± 21.74 133.97 ± 17.61
TCH2O (ml/kg/h) 0.55 ± 0.42 0.64 ± 0.27 0.58 ± 0.30 0.32 ± 0.60 0.59 ± 0.33 0.42 ± 0.41
EPGE2 (ng/kg/h) 2.96 ± 0.66 1.87 ± 0.69*** 2.47 ± 0.74 3.18 ± 0.50 2.08 ± 0.47** 2.64 ± 0.28
EAQP2 (pg/ml/h) 0.19 ± 0.11 0.17 ± 0.13 0.18 ± 0.10 0.18 ± 0.08 0.17 ± 0.06 0.17 ± 0.07
Values are mean ± SD. See Methods for calculations. Day/night differences: ** day/night p < 0.01 and *** day/night p < 0.001BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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Diurnal rhythm of urine osmolality, diuresis, excretion rates of PGE-2, AQP-2 and sodium in women with low (white) or high  (black) p-estradiol Figure 1
Diurnal rhythm of urine osmolality, diuresis, excretion rates of PGE-2, AQP-2 and sodium in women with low 
(white) or high (black) p-estradiol. Bars are mean ± SD.BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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Diurnal variation of clearance of sodium and osmoles, and solute free water reabsorption in natural cycling women with low  (white) and high (black) p-estradiol Figure 2
Diurnal variation of clearance of sodium and osmoles, and solute free water reabsorption in natural cycling 
women with low (white) and high (black) p-estradiol. Values are mean ± SD.BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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P-sodium, p-osmolality and packed cell volume in low (white) and high (black) estrogen states Figure 3
P-sodium, p-osmolality and packed cell volume in low (white) and high (black) estrogen states. Values are mean 
± SD.BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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0.80) or testosterone 1.50 ± 0.54 vs. 1.64 ± 0.62 nmol/l (p
= 0.30) between the two admissions.
Correlations
We found no correlation between AQP-2 excretion and
secretion of AVP or oxytocin, but a significant positive cor-
relation between AQP-2 and urine osmolality (r = 0.3107,
p = 0.0024) and reabsorption of free water (r = 0.3618, p
< 0.001). At night these correlations were even stronger
(0.5632, p = 0.02 and 0.6723, p = 0.004, respectively).
AVP correlated negatively to diuresis (r = -0.3553, p =
0.004) and positively to urine osmolality (r = 0.2856, p =
0.02). The similar correlations with oxytocin were insig-
nificant. Prolactin correlated with diuresis (r = -0.4240, p
< 0.001) and urine osmolality (r = 0.2737, p = 0.03).
There was a significant positive correlation between excre-
tion of sodium and osmoles and diuresis (r = 0.6830, p <
0.001 and r = 0.5945, p < 0.001, respectively).
Blood pressure
The measurements demonstrated a significant night time
decrease in mean arterial blood pressure (MAP) of
approximately 14% in both admissions (p < 0.001). There
was no difference in MAP between the first and second
admission.
Discussion
We were able to demonstrate a circadian rhythm of AVP,
ANP and aldosterone but not for oxytocin. The excretion
of AQP-2 does not appear to be circadian, whereas PGE-2
has a marked nocturnal decrease in excretion. All hor-
mones were unaffected by different concentrations of
endogenous estrogen. Furthermore we showed a differ-
ence in p-osmolality between the mid-follicular (low
estrogen) and the preovulatory phase (high estrogen).
Plasma sodium and packed cell volume changed in paral-
lel with plasma osmolality, suggesting a small increase in
plasma volume due to high endogenous estrogen. Urine
production did not change; neither did the renal excretory
variables between the two admissions, even though there
was a tendency towards sodium retention when estrogen
was high.
To test the hypothesis that different endogenous levels
estrogen alters the body fluid regulation and urine pro-
duction, we designed this study with an admission in
midfollicular phase (estrogen low) and an admission just
before estimated time of ovulation (estrogen high). We
selected the follicular phase, as the concentration of pro-
gesterone remains low in normal healthy subjects,
throughout the study period.
Examining the effects of high and low estrogen on urine
regulation and body fluid balance is complex in young
natural cycling women because of the constantly changing
concentration of sex hormones. Unfortunately seven of
the included women in the present study had to be
excluded prior to statistical handling due low concentra-
tion of estrogen in both admissions. A natural physiolog-
ical variation in the length of the menstrual cycle may be
an explanation.
A circadian rhythm in AVP is well-established. At least in
males [4-6]. Only a few circadian studies of AVP have
been conducted in females [8,17,18]. Former studies have
been able to demonstrate a rise in both the basal concen-
tration [7] and the magnitude of the nocturnal peak in
AVP in follicular phase of the menstrual cycle compared
to the luteal phase [8]. Other studies have failed to con-
firm changing basal AVP over the course of the menstrual
cycle [9-12,17]. Exogenous estrogen unopposed to pro-
gesterone increases basal concentration of vasopressin,
whereas progesterone in combination with estrogen low-
ers basal AVP-concentration [13-15]. Progesterone antag-
onizes the stimulatory effect of estradiol on vasopressin
secretion [15] thereby reducing the nocturnal rise in AVP
as well. In the present study we found identical plasma
concentrations of AVP and identical nocturnal peaks in
the two admissions. An explanation of this discrepant
finding could be that we admitted solely in the follicular
phase with similar levels of progesterone. Furthermore the
variations in AVP concentrations could be related to the
particular subtype of estrogen receptor activated. Young
premenopausal women express mainly estrogen-receptor-
β (ERβ), whereas postmenopausal women express estro-
gen-receptor-α (ERα)[31]. Since ERβ inhibits and ERα
stimulates AVP neuronal activity in the supraoptic nucleus
of the hypothalamus [32], this explains the elevated AVP
levels in postmenopausal women in response to estrogen
administration and the lack of increase in the present
study.
Over the past 20 years several studies have shown that the
operating point for AVP-release is shifted during the
course of the menstrual cycle. Observational studies have
shown a decrease in both plasma osmolality and sodium
with no change in p-AVP in the luteal phase of the men-
strual cycle [9,10] and in pregnancy [33]. Exogenous
estrogen and progesterone or stimulation with gonado-
tropins result in a similar resetting [16,20]. Evidence
favors the estrogenic component to be is responsible for
Table 3: Plasma-estradiol concentration in the two admissions
Mean ± SD
"low p-estradiol" – 1. admission 0.31 ± 0.08 (0.23–0.43)
"high p-estradiol" – 2. admission 0.95 ± 0.25 (0.69–1.33)*
Values are mean ± SD. *Low/high: p < 0.001BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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Circadian rhythm of the hormones ANP, AVP, oxytocin, aldosterone and prolactin in women with low and high p-estradiol Figure 4
Circadian rhythm of the hormones ANP, AVP, oxytocin, aldosterone and prolactin in women with low and 
high p-estradiol. The obtained difference in p-estradiol between low and high states is shown in the graph as well. Values are 
mean ± SD.BMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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the shift in osmoregulation [19,20]. We demonstrated a
decrease in plasma osmolality and sodium of approxi-
mately 2.5 mosm/kg and 0.5 mmol/l, respectively. This
equals only half the differences referred. This may be due
to the different experimental set up. We focused on the
effect of different concentration of estrogen unopposed to
progesterone and have made our investigations solely in
the follicular phase of the menstrual cycle. The greater dif-
ference found in previous studies may be due to the fact
that they have admitted the women in early follicular and
late luteal phase, thereby obtaining maximal difference in
plasma-estradiol [9,10]. In young women estrogen
administration will lower the osmotic threshold for AVP
release, but no effect on free water reabsorption has been
noted [19,21]. This has led to a suggestion that estrogen
may lower the renal tubular sensitivity to AVP as well.
Studies in rats show that estrogen inhibits AVP actions on
free water reabsorption [34]. However, estrogen adminis-
tration to young females does not affect the overall renal
sensitivity to AVP and it even appears that estrogen
increases the urine concentrating response within normal
physiological ranges of AVP [35]. In the present study we
did not observe any changes in reabsorption of free water
between the two states of estradiol, nor did we demon-
strate an increase in urine osmolality in high estrogen
states, indicating that elevations in estradiol seen in the
present study neither inhibits nor stimulates the AVP
response. The fluid retention during estrogen treatment is
therefore thought to be more related to increases in
sodium reabsorption. In the present study, high estradiol
– even though not quite significant – led to a strong ten-
dency towards decreases in sodium excretion, fractional
excretion of sodium and sodium clearance. This statistical
significance is however influenced by an extreme sodium
excretion in one of the participating women. Excluding
this participant on behalf of these data would be incorrect,
but a sensitivity analysis without her eliminates the statis-
tical significant difference in sodium excretion. In young
women administration of estradiol will increase sodium
reabsorption during AVP infusion [35]. Estrogen adminis-
tration have also led to greater sodium retention in
response to hypertonic saline infusion [21]. We were not
able to find significant sodium retention in the high-estra-
diol states, but several reasons could account from this
discrepant finding. 1) Our study is purely observational;
none of the physiological processes have been speeded
up. 2) Plasma-estradiol may be insufficiently increased in
the second admission. 3) Additionally the excretion of
sodium during the in-patent investigations reflects the
dietary intake of sodium at home as well. Participants
were fluid preconditioned 2 days prior to the admissions,
whereas sodium intake at home was not standardized.
Perhaps because of differences in the participants' habit-
ual sodium intake, the sodium intake during admission
(3 mmol/kg/day) did not fully sodium load some of the
participants while overload others.
In this study, we found no diurnal variation in concentra-
tion of oxytocin, but a variation in concentration between
the two admissions. This significance is however partly a
result of high values of oxytocin in one of the participating
women. Excluding her form the primary analysis would
eliminate the statistical significance, but still there would
be a strong tendency towards an increased oxytocin con-
centration in the second admission. Previous studies have
been able to demonstrate a fall in oxytocin during the day
in healthy young males [5,6] and a significant nocturnal
peak similar to the nocturnal peak in vasopressin release
[5]. However, Kostoglou-Athanassiou et al [8] found in
young women that p-oxytocin did not display diurnal var-
iation, nor could they find any difference between the fol-
licular and the luteal phase. Nevertheless other studies
done during day-time only have revealed increased oxy-
tocin concentrations at ovulation/midcycle [24,25].
Whether oxytocin in physiological doses plays a role in
antidiuresis is elusive. In the present study there was no
correlation between oxytocin and urine osmolality or diu-
resis, whereas the similar correlations with AVP were weak
but significant. Together with the lack of nocturnal
increase, this suggests that oxytocin in the present experi-
mental set up do not contribute to the overall antidiuretic
effect. In humans an antidiuretic effect of oxytocin has
however been demonstrated [22,23]. The antidiuretic
effect of oxytocin is believed to be mediated by the vaso-
pressin receptor, since infusion of oxytocin in healthy
young males produces an increase in AQP-2 excretion in
parallel with its antidiuretic effect [22]. Since the affinity
of oxytocin to the vasopressin receptor is much lower than
that of AVP, the antidiuretic effect will probably only
occur when supra-physiological doses of oxytocin are
being used.
The urinary AQP-2 excretion did not display a circadian
rhythm nor did it differ between the admissions. In
DDAVP induced antidiuresis AQP-2 excretion rates corre-
late well with urine osmolality [36,37], whereas a correla-
tion between the native AVP and AQP-2 excretion under
different experimental conditions (dehydrating experi-
ments or hypertonic saline infusion) is less obvious.
Under normal physiological conditions we would expect
the AQP-2 excretion to be higher during the night. The in-
patient studies were designed to resemble the daily life of
the participants and were purely observational. Examin-
ing the circadian rhythm in diuresis is very dependent on
a normal sleep pattern. If sleep is interrupted diuresis will
increase [38]. Blood sampling at night was carried out
with care not to wake the participants, and this was possi-
ble in most cases. Since none of the healthy volunteersBMC Urology 2008, 8:16 http://www.biomedcentral.com/1471-2490/8/16
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normally have nocturia or are awake at night, it would cer-
tainly interrupt their normal rhythm, if they were asked to
empty their bladder at night or were asked to have a drink
of water. Unfortunately this also entails, that the night
time urine production is pooled in the morning and a
possible increase in the excretion of AQP-2 at the time of
maximal antidiuresis will be blurred. A urethral catheter
could have been the solution, but the subsequent discom-
fort may disrupt the sleep and adversely affect the diurnal
rhythm. Furthermore a catheter may interfere with the
physiological processes of urine production and bladder
filling.
Urine production at home averaged 10 ml/kg less than
when the young women were admitted. Interestingly it
was only 24 h and day time urine volume, whereas night
time urine volume and day/night ratio were similar at
home and during admissions. Fluid intakes were similar.
Differences in extra renal fluid loss could explain this dis-
crepant finding. In the hospital the volunteers were basi-
cally less active than at home. It's a question, of course,
whether all voids were registered at home. The volunteers
were motivated and thoroughly informed of the impor-
tance of a precise registration. All FVC schemes were
examined carefully and no irregularities were detected.
The diurnal profile in the hospital may be different from
the profile at home, and the present data emphasize that
fluid balance reports are influenced by the setting of the
investigation.
Conclusion
This study is to the best our knowledge the first to describe
the diurnal urine regulation in women with focus on the
different concentrations of endogenous estrogen. The
study confirms the finding of a resetting of the osmore-
ceptors in high-estrogen states. We found that the hor-
mones involved in the diurnal urine regulation was
unaffected by the level of estradiol. Furthermore it appears
that oxytocin under normal physiological conditions has
no influence of the overall antidiuretic effect. This study
has however certain obvious limitations. Due to the large
irregularity of a normal regular menstrual cycle only half
of the participating women were actually included in the
statistical analysis. Furthermore it is possible that the dif-
ference obtained in the concentration of p-estradiol
between the first and second admission is too small to
actually alter the diurnal water homeostasis. More studies
of the influence of estrogen on the diurnal urine regula-
tion under normal physiological conditions are therefore
warranted.
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